Oftan (Timolol Maleate)

Timolol maleate blocks β‑adrenergic receptors in the ciliary body of the eye, which decreases the production of aqueous humor. The reduced fluid formation leads to lower intra‑ocular pressure, helping to prevent progression of glaucomatous damage.

The dosing regimen for Oftan is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Typically, one or two drops are instilled in the affected eye(s) once or twice daily, but the exact schedule must be individualized.

Timolol should be used during pregnancy or lactation only if the potential benefit outweighs the risk to the fetus or infant. Systemic absorption is low, but caution is advised, and the prescriber should evaluate the safety profile for each case.

To order Oftan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Oftan (timolol) is a non‑selective beta‑blocker, offering a well‑established efficacy profile for lowering intra‑ocular pressure. Compared with prostaglandin analogues, timolol may have a quicker onset but can cause systemic beta‑blockade effects, whereas prostaglandins often have fewer systemic concerns but may cause eyelash growth or iris pigmentation.

Store Oftan at ambient temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain sterility.

Oftan is administered as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place the prescribed number of drops into the conjunctival sac without touching the tip of the bottle to the eye or surrounding tissues.

Serious risks include significant bradycardia, heart block, severe hypotension, bronchospasm in patients with reactive airway disease, and systemic hypoglycaemia unawareness in diabetic patients. Any signs of these reactions require immediate medical attention.

Oftan is contraindicated in patients with known hypersensitivity to timolol or any component of the formulation, severe sinus bradycardia, second‑ or third‑degree heart block, uncontrolled asthma, or chronic obstructive pulmonary disease. It should also be used with caution in patients with diabetes, cardiovascular disease, or renal impairment.